Expression of c-MET in Invasive Meningioma

Sumi Yun, Jae Moon Koh, Kyu Sang Lee, An Na Seo, Kyung Han Nam, Gheeyoung Choe, Sumi Yun, Jae Moon Koh, Kyu Sang Lee, An Na Seo, Kyung Han Nam, Gheeyoung Choe

Abstract

Background: Meningiomas show high recurrence rates even after curative tumor removal. The invasiveness of meningiomas may contribute to their high recurrence rates. Recently, c-MET and hepatocyte growth factor (HGF) have been reported to be involved in cancer invasion.

Methods: We examined the immunohistochemical expression of c-MET and HGF in 100 cases of patients with meningiomas who have undergone complete tumor removal.

Results: c-MET(-High) and HGFHigh were found in 17% and 13% of meningiomas, respectively. Brain invasion was observed in 17.6% of c-MET(-High) meningiomas, but in only 2.4% of c-MET(-Low) meningiomas (p=.033). Bone/soft tissue invasion was observed in 23.5% of c-MET(-High) meningiomas and in 9.6% of c-MET(-Low) meningiomas (p=.119). HGF(-High) did not show statistical association with brain invasion or bone/soft tissue invasion. c-MET(-High) demonstrated shorter recurrence-free survival (RFS, 93.5±8.2 months vs 96.1±1.9 months); however, this difference was not statistically significant (p=.139). There was no association of HGF(-High) with RFS.

Conclusions: This study demonstrates that c- MET(-High) is associated with brain invasion of meningiomas, and that c-MET expression may be a useful predictive marker for meningioma recurrence. Patients with invasive meningiomas with high expressions of c-MET may be good candidates for targeted therapy using c-MET inhibitors.

Keywords: Hepatocyte growth factor; Immunohistochemistry; Meningioma; Neoplasm invasiveness; Proto-oncogene proteins c-MET.

Conflict of interest statement

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.
Immunohistochemical staining in meningiomas. (A) c-MET staining in tubular cells in normal kidney. (B) c-MET weak staining in meningioma. (C) c-MET moderate staining in meningioma. (D) c-MET strong staining in meningioma. (E) Hepatocyte growth factor (HGF) staining in colonic mucosa. (F) HGF weak staining in meningioma. (G) HGF moderate staining in meningioma. (H) HGF strong staining in meningioma.
Fig. 2.
Fig. 2.
Kaplan-Meier curves for recurrence-free survival according to the expression of c-MET and hepatocyte growth factor (HGF). (A) Analysis by c-MET expression status. (B) Analysis by HGF expression status. (C) Analysis by c-MET/HGF co-expression status.

References

    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon: IARC Press; 2007.
    1. Choy W, Kim W, Nagasawa D, et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus. 2011;30:E6.
    1. Karja V, Sandell PJ, Kauppinen T, Alafuzoff I. Does protein expression predict recurrence of benign World Health Organization grade I meningioma? Hum Pathol. 2010;41:199–207.
    1. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997;21:1455–65.
    1. Ildan F, Erman T, Göçer AI. Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up. Skull Base. 2007;17:157–71.
    1. Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol. 2009;95:367–75.
    1. Caltabiano R, Barbagallo GM, Castaing M, et al. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study. J Neurosurg Sci. 2013;57:139–51.
    1. Barresi V, Vitarelli E, Tuccari G, Barresi G. MMP-9 expression in meningiomas: a prognostic marker for recurrence risk? J Neurooncol. 2011;102:189–96.
    1. Fathi AR, Roelcke U. Meningioma. Curr Neurol Neurosci Rep. 2013;13:337.
    1. Alahmadi H, Croul SE. Pathology and genetics of meningiomas. Semin Diagn Pathol. 2011;28:314–24.
    1. Terzi A, Saglam EA, Barak A, Soylemezoglu F. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract. 2008;204:305–14.
    1. Kliese N, Gobrecht P, Pachow D, et al. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene. 2013;32:4712–20.
    1. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010;16:37–45.
    1. Guessous F, Zhang Y, diPierro C, et al. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem. 2010;10:28–35.
    1. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):S7–19.
    1. Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol. 2012;7:459–67.
    1. Martínez-Rumayor A, Arrieta O, Guevara P, et al. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett. 2004;213:117–24.
    1. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery. 2000;46:938–47.
    1. Kim NR, Chae YS, Lim WJ, Cho SJ. Expression of hepatocyte growth factor/c-met by RT-PCR in meningiomas. Korean J Pathol. 2011;45:463–8.
    1. Suh JH, Park JW, Lee C. ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients. Korean J Pathol. 2012;46:423–8.
    1. Bozkaya G, Korhan P, Cokakli M, et al. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer. 2012;11:64.
    1. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140–8.
    1. Palma L, Celli P, Franco C, Cervoni L, Cantore G. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg. 1997;86:793–800.
    1. Gabeau-Lacet D, Aghi M, Betensky RA, Barker FG, Loeffler JS, Louis DN. Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg. 2009;111:464–71.
    1. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15:2207–14.
    1. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas. Cancer. 2000;89:1102–10.
    1. Violaris K, Katsarides V, Sakellariou P. The recurrence rate in meningiomas: analysis of tumor location, histological grading, and extent of resection. Open J Mod Neurosurg. 2011;2:6–10.
    1. Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients: a multivariate analysis. Surg Neurol. 1986;26:461–9.
    1. Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int. 2001;51:172–8.
    1. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998;29:175–80.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner